Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

TransThera wins first China approval in post-FGFR cholangiocarcinoma

7 August 2026 · By · Wire by Fusion42

Published

7 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 7 August 2026 · Fusion42 review

China's NMPA granted conditional marketing approval to TransThera's tinengotinib (Yochanra) for patients with advanced cholangiocarcinoma who progressed after prior FGFR inhibitor treatment, marking the first approval in China for this post-FGFR population.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Cholangiocarcinoma drugmakers can now address a treatment gap post-FGFR inhibitor failure in China, opening a new patient niche and commercial opportunity this week.

◆ Coverage

1 source · 7 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfgfr-inhibitorcholangiocarcinomadrug-approvaloncologychinatransthera